Caixin News Agency, November 25th - Zaiding Pharmaceutical (09688/ZLAB) announced that it will complete the sale of a total of 7.84 million American Depositary Shares to the public on November 18, 2024, at a price of $25.5 per share, equivalent to approximately HKD 19.84. The total proceeds from this sale are approximately 230 million US dollars (approximately 1.789 billion Hong Kong dollars), and the net amount after deducting related expenses is 216 million US dollars (approximately 1.682 billion Hong Kong dollars). The underwriter has exercised the option to purchase an additional 1.18 million American depositary shares, and the related delivery will be completed on November 19, 2024.
The company plans to use the net proceeds for general corporate purposes, including continuing research and development of global pipelines, advancing commercialization of candidate products, and seeking strategic business development opportunities. The forward-looking statements mentioned in the announcement involve future expectations, plans, and prospects, which may be influenced by various factors, and actual results may differ significantly from expectations.